Colorectal Cancer Overview

Colorectal cancer occupies a unique position in oncology as one of the most common cancers globally yet also one of the most preventable. The disease, which develops in the colon or rectum, affects approximately 1.9 million people worldwide annually with about 900,000 deaths attributed to it. Despite this substantial burden, the disease is also remarkably amenable to prevention and early detection. Most colorectal cancers develop from precancerous polyps over 10 to 15 years, providing substantial opportunity for screening to identify and remove polyps before cancer develops or to detect early-stage cancers when treatment is most effective.

The biological basis of colorectal cancer reflects the typical progression from normal colon lining to adenomatous polyps to invasive cancer. The progression involves accumulation of multiple genetic and molecular changes including mutations in tumor suppressor genes (such as APC), oncogenes (such as KRAS), DNA mismatch repair genes, and various others. The slow progression typically over a decade or more provides the substantial opportunity for screening intervention.

The substantial improvements in colorectal cancer outcomes over recent decades reflect multiple factors including widespread implementation of screening programs, advances in surgical techniques, refined chemotherapy regimens, targeted therapies for specific molecular features, and immunotherapy for selected subtypes. Patients today face better outcomes than those diagnosed even 10 to 20 years ago.

This article examines colorectal cancer comprehensively. It explains what the disease is, identifies risk factors, discusses symptoms and screening, addresses diagnosis and staging, examines treatment approaches across stages, and frames prevention efforts.

For broader context, see Understanding Different Types of Cancer.

⸻

What Colorectal Cancer Is

Colorectal cancer originates from the inner lining (mucosa) of the colon or rectum. Most cases develop from precancerous polyps, particularly adenomatous polyps (adenomas), sessile serrated polyps, and various other precancerous lesions. The progression from polyp to cancer typically takes 10 to 15 years.

Most colorectal cancers are adenocarcinomas (originating from glandular epithelial cells). Various other less common types can occur including neuroendocrine tumors, lymphomas, sarcomas, and various others.

Locations

Colorectal cancer can occur throughout the colon and rectum: right (ascending) colon, transverse colon, left (descending) colon, sigmoid colon, and rectum. The specific location affects symptoms and treatment approaches.

Genetic and Molecular Pathways

Several genetic and molecular pathways underlie colorectal cancer development. The chromosomal instability pathway accounts for approximately 80 to 85 percent of cases, with APC gene mutations often initiating this pathway. The microsatellite instability (MSI) pathway accounts for approximately 15 percent of cases, driven by defects in DNA mismatch repair genes. The CpG island methylator phenotype pathway accounts for some cases. The various pathways have somewhat different characteristics and treatment implications.

Cancer development is a multistep process involving accumulation of multiple genetic changes over years. The slow process provides substantial opportunity for screening intervention.

For more on staging, see Colorectal Cancer Staging and Survival Rates.

⸻

Risk Factors

Various factors affect colorectal cancer risk.

Age

Age is the strongest risk factor. Most cases occur after age 50. Risk continues increasing with age. Younger-onset disease has been increasing in recent years.

Family History

Family history of colorectal cancer or polyps increases risk. The risk is higher with first-degree relatives affected, with affected relatives at younger ages, and with multiple affected relatives.

Hereditary Cancer Syndromes

Several hereditary syndromes substantially increase risk. Lynch syndrome (hereditary nonpolyposis colorectal cancer or HNPCC) accounts for approximately 3 percent of colorectal cancers. Familial adenomatous polyposis (FAP) accounts for less than 1 percent of cases. MUTYH-associated polyposis and various others also contribute. Patients with hereditary syndromes face substantially elevated risk warranting specialized care.

Personal History

Personal history affects risk including previous colorectal polyps, previous colorectal cancer, long-standing inflammatory bowel disease (Crohn disease or ulcerative colitis), and various others.

Lifestyle Factors

Various lifestyle factors affect risk including diet high in red and processed meats, diet low in fiber, fruits, and vegetables, excessive alcohol consumption, smoking, obesity, sedentary lifestyle, and various others.

Other Risk Factors

Type 2 diabetes is associated with elevated colorectal cancer risk. Race and ethnicity affect risk, with higher rates in African American populations. Various other medical conditions and factors also affect risk.

For more on prevention, see Cancer Risk Factors and Prevention: Understanding What Increases Risk and How to Reduce It.

⸻

Symptoms

Colorectal cancer symptoms vary and can be subtle, particularly in early stages.

Often Asymptomatic Early

Many early colorectal cancers are asymptomatic. The asymptomatic nature of early disease supports the importance of screening rather than waiting for symptoms.

Common Symptoms

Common symptoms include changes in bowel habits (constipation, diarrhea, alternating, narrowing of stool), blood in stool (visible or detected by testing), persistent abdominal pain or discomfort, feeling of incomplete bowel emptying (tenesmus), unexplained weight loss, fatigue and weakness, iron deficiency anemia, and various others.

Symptoms by Location

Symptoms can vary by tumor location. Right-sided cancers often produce iron deficiency anemia and vague abdominal symptoms. Left-sided cancers often produce visible blood and bowel habit changes. Rectal cancers often produce visible blood and tenesmus.

For more details, see Colorectal Cancer Symptoms and Early Warning Signs.

Persistent symptoms warrant evaluation: symptoms persisting more than several weeks, visible blood in stool, iron deficiency anemia in middle-aged or older men or postmenopausal women, and various others.

For more on related considerations, see Most Commonly Misdiagnosed Conditions.

⸻

Screening

Screening substantially affects colorectal cancer outcomes through prevention and early detection.

Why Screening Matters

Screening can identify polyps before they become cancer, detect cancers at earlier, more treatable stages, and substantially reduce colorectal cancer mortality.

Screening Methods

Various screening methods exist. Colonoscopy visualizes the entire colon and allows polyp removal, typically every 10 years if normal. Fecal immunochemical test (FIT) tests stool for blood, annually. Multitarget stool DNA test (Cologuard) tests stool for DNA markers and blood, every 1 to 3 years. Flexible sigmoidoscopy visualizes part of the colon, every 5 years. CT colonography is an imaging-based examination, every 5 years.

Recommendations

Current recommendations generally include screening starting at age 45 for average-risk individuals (recently lowered from 50), earlier or more frequent screening for higher-risk individuals, and continuing screening generally through age 75 with individualized decisions through age 85.

Risk-Based Adjustments

Various risk factors affect screening. Family history of colorectal cancer or polyps warrants earlier screening. Personal history of polyps requires more frequent surveillance. Inflammatory bowel disease warrants specialized surveillance. Hereditary syndromes warrant intensive specialized surveillance.

For more on related considerations, see Cancer Staging Explained in Detail: TNM System, Clinical Significance, and Treatment Implications.

⸻

Diagnosis

The diagnostic process for colorectal cancer typically involves several elements.

Colonoscopy

Colonoscopy is central to diagnosis. It visualizes the entire colon and rectum, identifies tumors, polyps, and various other findings, allows biopsy for tissue diagnosis, and allows removal of accessible polyps.

Biopsy, Pathology, and Molecular Testing

Biopsy provides definitive diagnosis through pathologic evaluation including confirmation of cancer type, histologic grade, and various molecular features. Molecular testing is now standard for colorectal cancer including microsatellite instability (MSI) status, KRAS, NRAS, BRAF mutations, HER2 amplification, and various others.

Staging Workup

Staging workup typically includes CT of the chest, abdomen, and pelvis, MRI of the pelvis for rectal cancer, PET-CT in selected situations, various blood tests, and CEA monitoring.

For more on diagnosis broadly, see How Cancer Is Diagnosed: From Initial Symptoms to Biopsy and Molecular Testing.

⸻

Staging

Staging determines extent of disease and guides treatment.

TNM System

The TNM system is used for colorectal cancer. T (Tumor) describes depth of invasion. N (Node) describes lymph node involvement. M (Metastasis) describes distant metastasis.

Survival by Stage

5-year survival varies substantially. Stage 0: approaching 100 percent. Stage I: approximately 90 to 95 percent. Stage II: approximately 75 to 85 percent. Stage III: approximately 50 to 75 percent. Stage IV: approximately 10 to 20 percent overall, with substantial individual variation and improving with modern therapies.

For detailed staging, see Colorectal Cancer Staging and Survival Rates.

⸻

Treatment

Treatment varies substantially by stage.

Stage 0 and Stage I Treatment

Stage 0 typically involves removal of the precancerous or in-situ lesion, often through colonoscopy. Stage I typically involves surgical resection; most patients require no additional treatment.

Stage II and Stage III Treatment

Stage II typically involves surgical resection with adjuvant chemotherapy for higher-risk cases. Stage III typically involves surgical resection plus adjuvant chemotherapy with FOLFOX (oxaliplatin-based) or CAPOX (capecitabine plus oxaliplatin), which substantially improves outcomes compared to surgery alone.

Stage IV Treatment

Stage IV treatment is more variable and includes systemic chemotherapy, targeted therapy (anti-EGFR antibodies for KRAS/NRAS wild-type tumors, anti-VEGF antibodies, BRAF inhibitor combinations), immunotherapy for MSI-high or DNA mismatch repair deficient tumors, surgical resection for selected patients with limited metastases (oligometastatic disease), liver-directed therapies for liver-predominant disease, and various others. For some Stage IV patients with oligometastatic disease, treatment with curative intent is possible.

Rectal Cancer Specific Considerations

Rectal cancer has specific considerations including often preoperative (neoadjuvant) chemotherapy and radiation therapy for Stage II and III, surgical approaches that differ from colon cancer surgery, and various sphincter-preservation considerations.

For more on side effects, see Side Effects of Cancer Treatments.

For more on consultation, see When Should You See an Oncologist? Early Warning Signs Explained.

⸻

Molecular Features and Personalized Treatment

Various molecular features increasingly guide treatment.

Microsatellite Instability (MSI)

MSI-high (MSI-H) tumors account for approximately 15 percent of colorectal cancers, have specific clinical features, respond well to immunotherapy, and may not benefit from certain chemotherapy regimens. Testing is now standard.

KRAS, NRAS, BRAF

KRAS and NRAS mutations affect response to anti-EGFR antibodies (cetuximab, panitumumab). BRAF mutations affect prognosis and treatment selection. KRAS G12C-specific inhibitors are emerging.

HER2 Amplification

HER2 amplification in a subset of colorectal cancers may guide HER2-targeted therapies.

Lynch Syndrome

Lynch syndrome involves germline mutations in DNA mismatch repair genes. Patients face elevated risk of colorectal and various other cancers (endometrial, ovarian, urothelial, gastric, and various others). Family member evaluation supports identification of others at risk.

For more on related considerations, see Most Commonly Misdiagnosed Conditions.

⸻

Prevention

Various approaches contribute to colorectal cancer prevention.

Screening as Primary Prevention

Screening is the most important prevention approach because polyps can be removed before becoming cancer, representing true primary prevention.

Lifestyle Modifications

Various lifestyle modifications may reduce risk including maintaining healthy weight, regular physical activity, diet rich in fruits, vegetables, and whole grains, limited red and processed meat consumption, limited alcohol consumption, avoiding tobacco, and various others.

Aspirin and Other Considerations

Aspirin has been associated with reduced colorectal cancer risk in some studies, but use specifically for cancer prevention involves balancing benefits with risks (particularly bleeding). Calcium and vitamin D have been associated with potentially reduced colorectal cancer risk in some studies. Discussion with healthcare providers addresses individual considerations.

⸻

Surveillance After Treatment

Patients treated for colorectal cancer require ongoing surveillance to detect recurrence early, identify new primary cancers, and address post-treatment issues. Typical surveillance includes periodic clinical visits, CEA monitoring, imaging studies, and surveillance colonoscopy. Frequency varies by initial stage and other factors, with more intensive surveillance appropriate for higher-stage disease.

⸻

Common Misconceptions

Several misconceptions about colorectal cancer deserve attention.

• Only older people get colorectal cancer — While more common with age, colorectal cancer can affect younger adults, and younger-onset disease has been increasing.
• No family history means no risk — Most colorectal cancers occur in patients without family history. Average-risk screening matters regardless.
• Symptoms always develop early — Many early cancers are asymptomatic. Screening is important rather than waiting for symptoms.
• Stage IV means no hope — Stage IV outcomes have improved substantially. Some patients achieve long-term survival or even cure.
• Colonoscopy is the only effective screening — Various screening methods are effective and support different patient situations.
• Treatment is identical for all colorectal cancers — Treatment varies substantially by stage, location, molecular features, and various other factors.
• Once cured, no further risk — Patients with previous colorectal cancer face continued risk requiring surveillance.

⸻

Special Patient Populations

Several specific situations have particular considerations.

Younger Adults

Younger adults face increasing colorectal cancer rates for unclear reasons. The trend has prompted screening start age reduction from 50 to 45. Persistent symptoms in younger adults warrant evaluation.

Patients With Hereditary Syndromes

Patients with Lynch syndrome, FAP, or various other hereditary syndromes warrant specialized care including earlier and more frequent surveillance, possibly prophylactic interventions, family member evaluation, and various others.

Patients With Inflammatory Bowel Disease

Patients with long-standing inflammatory bowel disease face elevated risk warranting close surveillance.

For more on related concerns, see Most Commonly Misdiagnosed Conditions.

⸻

When to See a Specialist

Various specialists are involved in colorectal cancer care. Primary care physicians often initiate evaluation and refer for screening. Gastroenterologists perform colonoscopy and provide initial evaluation. Colorectal surgeons or general surgeons perform resection. Medical oncologists manage chemotherapy and various medical treatments. Radiation oncologists manage radiation therapy when indicated. Genetic counselors evaluate hereditary cancer concerns. For complex situations, evaluation at major cancer centers provides specialized expertise.

⸻

Conclusion

Colorectal cancer is one of the most common cancers globally yet also one of the most preventable. The disease develops in the colon or rectum, typically progressing slowly from precancerous polyps over 10 to 15 years. The slow progression provides substantial opportunity for screening to identify and remove polyps before cancer develops or detect early-stage cancers when treatment is most effective.

Risk factors include age (most cases after 50, but increasing in younger adults), family history, hereditary cancer syndromes (Lynch syndrome, FAP, MUTYH-associated polyposis, and various others), personal history (polyps, previous cancer, inflammatory bowel disease), lifestyle factors (diet, alcohol, smoking, obesity, sedentary lifestyle), type 2 diabetes, race and ethnicity, and various others.

Screening identifies polyps before cancer development and detects cancers at earlier stages. Various methods include colonoscopy (every 10 years if normal), FIT (annually), Cologuard (every 1 to 3 years), flexible sigmoidoscopy (every 5 years), and CT colonography (every 5 years). Recommendations include screening starting at age 45 for average-risk individuals.

Treatment varies by stage. Stage 0 typically involves polyp removal. Stage I involves surgery alone in most cases. Stage II may involve surgery with consideration of adjuvant chemotherapy. Stage III involves surgery plus adjuvant chemotherapy (FOLFOX or CAPOX). Stage IV involves systemic therapy with various individualized approaches including targeted therapy, immunotherapy for MSI-high tumors, and selective surgery for oligometastatic disease.

Molecular features increasingly guide treatment. MSI-H (15 percent) responds well to immunotherapy. KRAS/NRAS mutations affect anti-EGFR response. BRAF mutations affect prognosis and treatment. HER2 amplification may guide therapy. Lynch syndrome warrants specialized care.

The encouraging element is that colorectal cancer is among the most preventable and treatable cancers when detected early. Modern advances continue to improve outcomes.

⸻

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.